Introduction
The role of allogeneic transplantation for lymphoma is continually redefined as a result of advances in conventional treatments, in transplant technology, in diagnostic methods and in prognostic tools. Allogeneic transplantation for lymphoma is usually considered in the salvage setting, as an alternative to autologous stem cell transplantation (auto-SCT) or after failure of autologous transplantation. This review will focus on allogeneic transplantation for aggressive lymphoma, the largest subgroup of which is comprised of diffuse large B-cell lymphoma (DLBCL). But numerous other subtypes exist some of which will be discussed.
Allogeneic transplantation: comparison with autologous transplantation and graft vs. lymphoma effects
It is generally and probably correctly assumed that allogeneic transplantation is both more effective and more toxic than autologous transplantation. Early retrospective observations [1] [2] [3] [4] [5] were followed by a prospective study, in which patients with matched siblings were assigned to allogeneic transplantation, all others to autologous [6] . There was no complete balance between the groups since those undergoing allogeneic transplant more frequently had a history of bone marrow involvement and of chemotherapy-resistant disease. Despite this, there was
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Keywords allogeneic, adult T-cell leukemia-lymphoma, diffuse large B-cell lymphoma, graft vs. lymphoma, lymphoma, peripheral T-cell lymphoma a significantly lower incidence of relapse after allogeneic transplant and a nonsignificant improvement in survival (Fig. 1a) . Similarly, the transplant centers in Ontario, using allo-transplant preferentially for those with bone marrow involvement or an inadequate bone marrow harvest, found a lower rate of disease recurrence after allogeneic transplantation [7] . But the advantages of allogeneic transplant were at least partially offset by an increased rate of treatment related mortality (TRM; Fig. 1b) . The European Registry confirmed this in a large registry study [8] . A recent CIBMTR study comparing allogeneic with autologous transplant in DLBCL was not able to show any benefit to allogeneic transplantation [9 ] . In this study relapse rates after allogeneic and autologous transplantation were found to be similar after adjustment for various prognostic factors. Similarly, Gross et al. studying pediatric patients did not find much advantage for allogeneic transplantation except in the subgroup with lymphoblastic lymphoma. There seems therefore a considerable discrepancy between the results of the few more or less prospective comparisons [6, 7] and the registry analysis or retrospective comparisons. The reasons are multiple and include imbalances in patient characteristics, heterogeneity of disease histologies and differences in treatment protocols. Allorecipients tend to be younger, have more advanced disease, more frequent marrow involvement and receive total body irradiation (TBI) more commonly. Other important determinants of outcome such as serum lactate dehydrogenase (LDH) or PET scan results, measures of performance status or comorbidities are rarely included [10, 11] . Also, most studies report on patients accrued over long periods of time, during which improvements in supportive care and in HLA-typing have resulted in steady improvement in allogeneic transplant results [12] . So, the results may no longer be representative of current outcomes of allogeneic transplantation. By contrast, no major changes have occurred in autologous transplantation over the past decade.
Graft vs. lymphoma effects
The most definitive evidence of graft vs. lymphoma (GVL) effects remains the clinical observation of lymphoma regression after withdrawal of immunosuppression or after infusion of donor lymphocytes [2, 13, 14] . In fact, one of the earliest observations of graft vs. leukemia effects in humans was made in a patient with Burkitt's disease, recurring after allogeneic bone marrow transplantation, whose disease responded to withdrawal of immunosuppressive therapy [2] . We also observed, responses to donor lymphocyte infusion (DLI) or withdrawal of graft vs. host prophylaxis in six of nine patients recurring after transplantation [13] (Fig. 2) . In general though, responses to DLI or to withdrawal of immunosuppression appear more frequent in patients with indolent histologies than in those with aggressive histologies [15 ,16] . GVL effects may also be more clinically important in certain disease histologies such as in peripheral T-cell lymphoma (PTCL).
A second way in which GVL effects can be demonstrated is by the analysis of the relationship between graft vs. host disease (GVHD) and disease recurrence after allogeneic transplantation. In one retrospective study by the EBMTR, a lower recurrence rate was found for patients with chronic GVHD (cGVHD) vs. those without cGVHD (0 vs. 35%; P ¼ 0.02) [4] . In other studies of intermediategrade lymphoma, no relation between the incidence of GVHD and disease recurrence could be demonstrated [17] . Apart from the presence of GVL effects, the lack of involvement by lymphoma cells in the graft may also contribute to a decreased recurrence rate after allogeneic transplantation. There is considerable evidence that, in autologous transplantation, the infusion of occult lymphoma cells contributes in many cases to disease recurrence [18] . CIBMTR and EBMTR several years ago conducted a joint study of syngeneic transplants, the recurrence rate of which was lower than that of autologous transplants and similar to that of allogeneic transplants, suggesting that GVL effects are less important in lymphoma [19] .
Conditioning regimens
TBI, initially introduced for its antileukemic activity and immunosuppressive effects, long constituted the backbone of allogeneic transplantation [20] . But TBI is toxic. Mucositis can be debilitating and is further exacerbated by post-transplant methotrexate [21] . Renal, hepatic and particularly pulmonary toxicity are life-threatening and TBI has been used rarely in older patients [3, 22] . Concerns over toxicity led to the development of novel 682 Hematologic malignancies
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conditioning regimens often labeled reduced intensity conditioning (RIC) regimens or nonmyeloablative (NMA) regimens. Numerous studies have been reported. But the terminologies of RIC and NMA imply reduced toxicity, and are therefore somewhat self-fulfilling and potentially misleading [23] . They also mask the considerable heterogeneity of the various regimens, labeled as RIC or NMA by committee decision [24, 25] . GVHD-related complications may be more common a cause of TRM than toxicities from conditioning, an issue not addressed by modifying the conditioning regimens [26] . After more than a decade of work, there is no definitive answer to the question of superiority of any regimen. The best evidence of advantages for RIC comes from Seattle studies demonstrating improved survival after NMA conditioning, but only in those with considerable comorbidities [27] . In most other studies, early TRM has been somewhat reduced, but late TRM due to GVHD and related complications may be higher. Relapse is similar or increased compared with myeloablative transplants [28, 29] . Overall, considerable questions linger over which transplant regimen is optimal. There may be differences in outcome due to more or less intensive regimens, but overall outcome is affected considerably more by patient and disease-related characteristics.
Be it as it may, full-dose TBI-based regimens are rarely utilized, particularly in cases of lymphoma. The Seattle NMA conditioning regimen involving low doses Reproduced with permission from [6] . (b) Results of a prospective study in Ontario whereby patients with poor marrow harvests or with bone marrow involvement preferentially underwent allo transplant. (1) relapse-free survival and (2) relapse rate. Reproduced with permission from [7] .
of TBI is a common choice but associated with high rates of recurrence in patients with active disease. In a recent study the Seattle group combined their NMA conditioning with ibritumomab tiuxetan, a radio-labeled anti-CD20 and reported a 35% long-term progression free survival in a group of patients with advanced and often bulky disease, though the results were superior in patients with indolent lymphomas [30] .
Other commonly used conditioning regimens involve busulfan or melphalan in combination with other agents.
In the 1990s, we prospectively studied the tri-alkylator regimen consisting of thiotepa-busulfan and cyclophosphamide and found an approximately 30% long-term remission rate in patients with refractory lymphoma [31] . Others used busulfan-cyclophosphamide or busulfan cyclophosphamide-etoposide [32] . More recently though, most studies have involved intravenous busulfan, often with area under the curve monitoring and encouraging results have been reported in lymphoma patients [33, 34] .
The BEAM regimen (BCNU, etoposide, cytarabine, melphalan) is commonly used in autologous transplantation and was developed by our group for use in allogeneic transplantation [35] . We found an approximately 40% long-term survival including durable remissions in a large fraction of patients with refractory lymphoma and concluded that the BEAM regimen might be optimal for patients with lymphoma. Our encouraging results were subsequently confirmed by a British group who found an excellent long-term survival with limited toxicity and by the Stanford group who used a variant, cyclophospamide-BCNU-etoposide [36, 37] . More commonly fludarabine melphalan is utilized. This regimen has resulted in favorable long-term outcomes [38, 39 ] .
Graft vs. host disease prophylaxis
GVHD can be beneficial by preventing relapse and detrimental by causing chronic morbidity and late deaths. The concept of RIC is built on exploiting GVL effects. The Seattle group in particular has found that acute GVHD is to be avoided because it increases TRM; in their experience cGVHD prevents recurrence without increased TRM [40] . Such data do not take into account the serious morbidity associated with cGVHD and its impact on very long-term survival. cGVHD and/or its treatment are the major risk factors for many late complications including infertility, early menopause, osteonecrosis, chronic pulmonary and cardiac problems and increased risk for skin cancer [41] [42] [43] 44 ] . Transplant patients in remission face an ongoing risk of death that well exceeds that of an age-matched population and cGVHD is a major risk factor for late death after transplant [41, 44 ]. Avoidance of late cGVHD underlies our interest, and that of other groups in T-cell-depleted transplant, usually using in-vivo alemtuzumab or antithymocyte globulin [36,38,39 ,45] . Many studies, usually nonrandomized, have compared the outcomes of T-depleted transplant and, with few exceptions, have shown a somewhat increased rate of disease recurrence but no effect on survival [46] [47] [48] . Some studies, using profound in-vitro T-cell depletion have, however, shown a very high early recurrence rate [49] . It may therefore well be that outcomes depend on the T-cell depletion technology utilized and on the lymphocyte subpopulations that are removed. Also, T-cell depletion increases the risk of early opportunistic infections and an effective strategy for CMV and Epstein Barr virus (EBV) detection and treatment is essential [50] [51] [52] .
Others have used sirolimus, an immunosuppressant with antineoplastic activity, in lymphoid malignancies. Sirolimus has reduced the incidence of acute GVHD, but not of cGVHD. In at least one study it was associated with a reduced incidence of disease recurrence [53] .
Donor source
Most older studies of transplant for lymphoma are restricted to recipients of matched sibling transplant, which are available for fewer than half of the patients and which are increasingly problematic as we consider transplant for older individuals and knowledge of the genetic basis of disease increases. We currently estimate that we reject approximately 10% of our potential sibling donors because of comorbidities -older recipients have older and sicker donors [54] . Interestingly, there are also increasingly frequent studies of clonal hemato-lymphopoiesis or genetic lesions in siblings of potential transplant recipients [55, 56] . ]. As donor typing becomes more accurate, it is also clear that many patients, particularly those of minority descent, lack matching donors [62] . Alternative donor transplant, that is haploidentical and/or cord blood transplantation, is increasingly considered. Of interest reduced intensity haploidentical transplantation as proposed by the Hopkin's group appears to have an excellent antitumoral effect with great rates of disease control, in contrast to the high rate of disease progression in myeloid diseases [63] . Umbilical cord blood transplantation appears reasonably effective as well [64] . Donor availability should therefore no longer constitute a major limitation for patients in need of allogeneic stem cell transplantation (allo-SCT).
Allogeneic transplantation for recurrent or refractory intermediate-grade lymphoma
DLBCL is by far the most common subtype among the aggressive lymphomas. Several categories can be recognized based on molecular features. The most common categories include germinal center B-cell (GCB)-like, non-GCB-like, and those with primary mediastinal B-cell lymphoma (PMBL) [65] . Furthermore, MYC translocations and in particular the double hit bcl2-Myc translocation are increasingly reported as having poor prognostic implications [66, 67] . The implications for allogeneic transplantation are unclear at present, though we have avoided allo-transplant in PMBL which appears to be exquisitely susceptible to dose intensification [68] [69] [70] .
Transplantation is commonly used in the management of patients with recurrent DLBCL. Comparisons between auto and allo have never convincingly demonstrated a survival benefit and often have also failed to show major differences in recurrence rates [1, [3] [4] [5] [6] 8, 9 ]. Autologous transplantation tends to be favored because of its feasibility, low TRM and proven track record [71] . But the results of the Coral study raise concern over the effectiveness of autologous transplantation in the rituximab era. Those failing rituximab-based first-line chemotherapy had dismal outcomes with autologous transplantation [72 ] . This may raise interest in allogeneic transplantation anew.
Until now though, we have limited allogeneic transplantation to patients who have adverse features for autologous transplantation, particularly those with refractory disease and/or multiple recurrences. A large number of studies show that allogeneic transplantation can be curative in a fraction of patients with otherwise refractory disease [2, 3, 17, 22, 26, 31, 34, 35, 37, 58, [73] [74] [75] [76] [77] [78] [79] [80] [81] .
Still the same rules that govern prognosis of autologous transplant are operative after allogeneic. Having refractory disease remains an adverse prognostic feature. Those who fail to respond to chemotherapy and come to transplant without radiologic response or with an elevated LDH are unlikely to do well; only a small fraction will be cured [26,32,39 ,58,81,82] . By contrast, several investigators find that findings of PET positivity have no impact for response to allogeneic transplant [39 ,83 ] . Patients with partial responses to salvage and normal LDH but residual PET-positive areas may be good candidates for allogeneic transplant (Fig. 3) . This needs to be confirmed in prospective studies, particularly since others continue to find prognostic value in PET scans [84 ] . At least one group found that patients with stable disease have a reasonable outcome after allogeneic transplant in contrast to those with progressive disease [85, 86] . When measured, performance status and comorbidity assessment also strongly correlate with long-term outcome [47, 59, 84 ]. So, though allogeneic transplant may be effective in some patients who would be categorized as refractory based on lack of radiologic response (i.e. stable disease) or failure to resolve all PET positivity, it is unlikely to be effective in those with truly progressive disease and worsening radiologic findings or an increased LDH. 
Allogeneic after failure of autologous transplantation
Allogeneic transplantation has also commonly been used after failure of autologous transplant, particularly in patients with DLBCL. An initial study by Freytes et al.
[87] found poor outcomes for such patients. The majority of patients relapsed again, but duration of response was largely dependent on whether the disease was still chemotherapy-sensitive prior to transplant [87] . Subsequent studies, often using RIC showed better outcomes, with durable remissions occurring in 20-40% of patients [88,89 ,90,91 ,92] . In aggregate the data indicate that patient (performance status, albumin) -and diseaserelated factors (duration of remission, extent of disease, chemotherapy sensitivity) -predict outcome, more than any particular conditioning regimen utilized. Baron et al. [92] found that cGVHD was associated with decreased risk for disease recurrence. Whereas such data are often considered demonstrations of the power of GVL effects, durable remissions have also occurred after second autologous transplantation [93] .
Allogeneic transplantation for Burkitt's lymphoma
Very little has been reported on allogeneic transplantation for patients with recurrent Burkitt's lymphoma. It is a disease that is occasionally susceptible to GVL effects and some of the earliest studies on this phenomenon concerned patients with Burkitt's lymphoma [2, 14] . But Burkitt's lymphoma is also highly curable with intensive chemotherapy [94] . For those with recurrent Burkitt's lymphoma, the risk of recurrence after allogeneic transplant is extremely high. In an early series, we found among 14 adults with refractory Burkitt's disease, only one long-term remission. Very early relapse accounted for the majority of failures [95] . Similar outcomes were recently reported for pediatric patients [96 ] . Only about 30% were long-term survivors and the rate of early disease recurrence was 70%.
Peripheral T-cell lymphoma, mycosis fungoides and natural killer cell lymphoma
Approximately 10-20% of lymphomas are of T or natural killer (NK)-cell lineage and constitute considerable challenges because of their complexity and in general their worse prognosis [97] . Emerging data suggest a considerable role for allogeneic transplantation in these disorders. Advanced mycosis fungoides can be an aggressive disease at times impossible to control with conventional chemotherapy. Several studies indicate that allogeneic transplantation, in contrast to autologous, can be curative, sometimes even in patients with very refractory disease [98, 99 ,100]. Molina et al. [98] were among the first to document a high rate of durable responses in a series of eight patients undergoing allogeneic transplantation. Similar results were reported by the MD Anderson group [101] . Wu et al. [102] in a meta-analysis find that remissions are more frequent and more prolonged after allogeneic than after autologous transplantation. A registry study found prolonged survival in the majority of patients [99 ] . Responses and response duration depended on the stage of disease. Relapse was more common after T-depleted transplant, but was not dependent on the conditioning regimen. After relapse, many patients responded to salvage therapy including DLIs, suggesting a strong susceptibility to GVL effects of this disorder.
PTCL is highly heterogeneous and some subtypes are extremely aggressive. In some cases, allogeneic transplant offers the only chance for cure. For example, hepatosplenic T-cell lymphoma, an otherwise incurable disorder, has occasionally been cured with allogeneic transplantation [101] . Similarly recurrent and refractory angioimmunoblastic T-cell lymphoma can be cured by allogeneic transplant. Outcome correlates with chemotherapy sensitivity prior to transplant [103] . Woessman et al. [104] reported impressive outcomes in pediatric patients undergoing allogeneic transplant for relapsed and refractory anaplastic large cell lymphoma. This may be of particular interest given the recent development of a brentuximab, a conjugated anti-CD30 with an impressive but transient rate of response in anaplastic large cell lymphoma [105] . Such patients may then be consolidated with allo-transplant. The majority of patients with PTCL have lymphomas that cannot be further classified, so called PTCL NOS (not otherwise specified). Studies from several groups show high cure rates with allogeneic transplant in such patients often using RIC [106] [107] [108] [109] [110] . Many of these studies indicate responses to DLI or other immune manipulations or attribute the occurrence of response to GVL effects. Whether the results of allogeneic transplantation are truly superior to those of autologous transplantation or of conventional chemotherapy continues to be debated [111] . Jacobsen et al. [112 ] from the Dana Farber group, in an interesting study, find that allogeneic transplant is particularly successful for patients with nodal T-cell lymphoma and less so for extranodal disease.
NK cell lymphoma is a devastating EBV-driven lymphoma that is quite common in the Far East and South America but also regularly encountered in Europe and the USA. Many patients present with involvement of the sino-nasal area, but other presentations are also common. Until recently radiation therapy was the mainstay of treatment and was combined with chemotherapy. Emerging data suggest a major role for asparaginase in its treatment [113] . Many patients still relapse, but allogeneic transplantation has been shown to be curative, particularly in younger patients with chemotherapy sensitive recurrences [114, 115, 116 ]. The importance of GVL effects in this disorder is underscored by response to DLI [117] .
Adult T-cell leukemia-lymphoma (ATLL), caused by chronic infection with the HTLV-1 virus, is common in Japan and in some Caribbean islands. The disease, when aggressive, can only be cured by allogeneic transplantation. Many patients are elderly and have comorbidities and TRM has been a concern [118] . After relapse responses to withdrawal of immunosuppression have been frequently observed [119, 120 ] . The prevalence of occult HTLV-1 infection is high in endemic areas and many HLA-identical siblings are infected with the virus. Use of donors who are HTLV-1-positive is associated with an increased rate of complications [120 ] .
Relapse
When relapse occurs in patients with aggressive lymphoma it often happens within the first 6 months after transplant and the prognosis for such early relapsing patients is poor. Few if any such patients obtain durable remissions to further chemotherapeutic or immunologic intervention [39 ,121 ,122,123] . Occasional patients, particularly those with late relapses, respond to further interventions and appear susceptible to GVL effects. Because of the poor prognosis of early relapsing patients, some have recommended preemptive therapy with DLI when mixed chimerism is observed [124] . This approach is controversial since DLI can induce GVHD and since others have not found mixed chimerism to be predictive of disease recurrence [58, 125] . Others have administered prophylactic DLI and rituximab to prevent relapse and report encouraging pilot data [126] . Any prophylactic or preemptive therapy should be carefully tested in prospective studies before being widely adopted, particularly since the toxicity profile of various medications can change dramatically when administered after allogeneic transplant [127 ] .
Conclusion
Allo-SCT is a curative treatment for various subtypes of aggressive lymphoma. In DLBCL it is the treatment of choice for patients failing autologous transplantation and for patients with partial response to salvage therapy [128 ] . It may be used more in the future as autologous transplant has been found to be rather ineffective in patients failing rituximab-based frontline therapy. Allogeneic transplantation is emerging as the treatment of choice in PTCL and NK cell lymphoma. Further study is needed to identify conditioning regimens with improved efficacy and reduced toxicity.
